Treatment of essential thrombocythemia

被引：2

作者：

Alvarez-Larran, Alberto ^{[1
]}

Cervantes, Francisco ^{[2
]}

Besses, Carlos ^{[1
]}

机构：

[1] Univ Autonoma Barcelona, Serv Hematol, Hosp del Mar, Inst Hosp del Mar Invest Med IMIM, E-08193 Barcelona, Spain

[2] Univ Barcelona, Serv Hematol, Hosp Clin, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

来源：

MEDICINA CLINICA | 2013年 / 141卷 / 06期

关键词：

Essential thrombocythemia; Treatment; Risk factors; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; LEUKOCYTE ACTIVATION; MYELOID METAPLASIA; HIGH-RISK; HYDROXYUREA; MUTATION; THROMBOSIS; COMPLICATIONS; PLATELET;

D O I：

10.1016/j.medcli.2013.01.016

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage. The goal of treatment is to prevent the development of vascular complications without increasing the risk of transformation. Patients aged > 60 years or a history of thrombosis have a high risk of thrombosis while those with a platelet count > 1,500 x 10(9)/l have a higher risk of hemorrhage. Patients with low-risk essential thrombocythemia can be managed appropriately with low-dose of acetylsalicylic acid or even observation only, while patients with a high-risk disease are candidates to receive cytoreductive treatment, hydroxyurea being the first choice therapy. Anagrelide is the most suitable option for patients with resistance or intolerance to hydroxyurea. All patients must be submitted to a rigorous control of cardiovascular risk factors. (C) 2012 Elsevier Espana, S.L. All rights reserved.

引用

页码：260 / 264

页数：5

共 38 条

[1] POLYCYTHEMIA-VERA - STEM-CELL AND PROBABLE CLONAL ORIGIN OF DISEASE [J].

ADAMSON, JW ;

FIALKOW, PJ ;

MURPHY, S ;

PRCHAL, JF ;

STEINMANN, L .

NEW ENGLAND JOURNAL OF MEDICINE, 1976, 295 (17) :913-916

[2] Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia [J].

Alvarez-Larran, Alberto ;

Cervantes, Francisco ;

Pereira, Arturo ;

Arellano-Rodrigo, Eduardo ;

Perez-Andreu, Virginia ;

Hernandez-Boluda, Juan-Carlos ;

Ayats, Ramon ;

Salvador, Carlos ;

Muntanola, Ana ;

Bellosillo, Beatriz ;

Vicente, Vicente ;

Hernandez-Nieto, Luis ;

Burgaleta, Carmen ;

Xicoy, Blanca ;

Besses, Carlos .

BLOOD, 2010, 116 (08) :1205-1210

[3]

Arellano-Rodrigo E, 2006, HAEMATOL-HEMATOL J, V91, P169

[4] Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden [J].

Arellano-Rodrigo, Eduardo ;

Alvarez-Larran, Alberto ;

Reverter, Juan-Carlos ;

Colorner, Dolors ;

Villarnor, Neus ;

Bellosillo, Beatriz ;

Cervantes, Francisco .

AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (02) :102-108

[5] Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) [J].

Barbui, Tiziano ;

Finazzi, Guido ;

Carobbio, Alessandra ;

Thiele, Juergen ;

Passamonti, Francesco ;

Rumi, Elisa ;

Ruggeri, Marco ;

Rodeghiero, Francesco ;

Randi, Maria Luigia ;

Bertozzi, Irene ;

Gisslinger, Heinz ;

Buxhofer-Ausch, Veronika ;

De Stefano, Valerio ;

Betti, Silvia ;

Rambaldi, Alessandro ;

Vannucchi, Alessandro M. ;

Tefferi, Ayalew .

BLOOD, 2012, 120 (26) :5128-5133

[6] Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet [J].

Barbui, Tiziano ;

Barosi, Giovanni ;

Birgegard, Gunnar ;

Cervantes, Francisco ;

Finazzi, Guido ;

Griesshammer, Martin ;

Harrison, Claire ;

Hasselbalch, Hans Carl ;

Hehlmann, Rudiger ;

Hoffman, Ronald ;

Kiladjian, Jean-Jacques ;

Kroeger, Nicolaus ;

Mesa, Ruben ;

McMullin, Mary F. ;

Pardanani, Animesh ;

Passamonti, Francesco ;

Vannucchi, Alessandro M. ;

Reiter, Andreas ;

Silver, Richard T. ;

Verstovsek, Srdan ;

Tefferi, Ayalew .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) :761-770

[7] A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group [J].

Barosi, G. ;

Besses, C. ;

Birgegard, G. ;

Briere, J. ;

Cervantes, F. ;

Finazzi, G. ;

Gisslinger, H. ;

Griesshammer, M. ;

Gugliotta, L. ;

Harrison, C. ;

Hasselbalch, H. ;

Lengfelder, E. ;

Reilly, J. T. ;

Michiels, J. J. ;

Barbui, T. .

LEUKEMIA, 2007, 21 (02) :277-280

[8] Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference [J].

Barosi, Giovanni ;

Birgegard, Gunnar ;

Finazzi, Guido ;

Griesshammer, Martin ;

Harrison, Claire ;

Hasselbalch, Hans Carl ;

Kiladjian, Jean-Jacques ;

Lengfelder, Eva ;

McMullin, Mary Frances ;

Passamonti, Francesco ;

Reilly, John T. ;

Vannucchi, Alessandro M. ;

Barbui, Tiziano .

BLOOD, 2009, 113 (20) :4829-4833

[9] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[10] Major vascular complications in essential thrombocythemia:: a study of the predictive factors in a series of 148 patients [J].

Besses, C ;

Cervantes, F ;

Pereira, A ;

Florensa, L ;

Solé, F ;

Hernández-Boluda, C ;

Woessner, S ;

Sans-Sabrafen, J ;

Rozman, C ;

Montserrat, E .

LEUKEMIA, 1999, 13 (02) :150-154

← 1 2 3 4 →